The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):283-8. doi: 10.1016/s0960-0760(03)00368-6.


Aromatase inhibitors have now been approved as first-line treatment options for hormone-dependent advanced breast cancer. When compared to tamoxifen, these aromatase inhibitors provide significant survival and tolerability advantages. However, the optimal use of an aromatase inhibitor and tamoxifen remains to be established. To date, the intratumoral aromatase xenograft model has proved accurate in predicting the outcome of clinical trials. Utilizing this model, we performed long-term studies with tamoxifen and letrozole to determine time to disease progression with each of the treatment regimens. Aromatase-transfected MCF-7Ca human breast cancer cells were grown as tumor xenografts in female ovariectomized athymic nude mice in which androstenedione was converted to estrogen and stimulated tumor growth. When tumor volumes were approximately 300 mm3, the animals were grouped for continued supplementation with androstenedione only (control) or for treatment with letrozole 10 microg per day (long-term), tamoxifen 100 microg per day (long-term), letrozole alternating to tamoxifen (4-week rotation), tamoxifen alternating to letrozole (4-week rotation), or a combination of the two drugs. Tumors of control mice had doubled in volume in 3-4 weeks. In mice treated with tamoxifen and the combination, tumor doubling time was significantly shorter (16 and 18 weeks, respectively) than with letrozole (34 weeks). Furthermore, alternating letrozole and tamoxifen treatment every 4 weeks was less effective than letrozole alone. Tumors doubled in 17-18 weeks when the starting treatment was tamoxifen and in 22 weeks when the starting treatment was letrozole. Tumors progressing on tamoxifen remained sensitive to second-line therapy with letrozole (10 microg per day). However, when mice with letrozole-resistant tumors were switched to antiestrogen treatment, tumors did not respond to tamoxifen (100 microg per day) or faslodex (1 mg per day). This suggests that advanced breast cancers treated with letrozole may be insensitive to subsequent second-line hormonal agents. Thus, although letrozole was determined to be an effective second-line treatment option for tumors progressing on tamoxifen, antiestrogen therapy does not appear to be effective for tumors progressing on letrozole. However, response to second-line treatment was observed in a model where tumors that had progressed on letrozole were transplanted to new mice. These tumors had been allowed to grow in the presence of supplemented androstenedione but absence of letrozole. This suggests that resistance to letrozole may be reversible, allowing tumors to respond to subsequent antiestrogens and letrozole.

MeSH terms

  • Androstadienes / pharmacology
  • Androstadienes / therapeutic use
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Aromatase Inhibitors*
  • Cell Line, Tumor
  • Disease Models, Animal
  • Drug Administration Schedule
  • Enzyme Inhibitors / pharmacology*
  • Estrogen Antagonists / pharmacology*
  • Female
  • Humans
  • Letrozole
  • Mammary Neoplasms, Experimental / drug therapy
  • Mammary Neoplasms, Experimental / enzymology*
  • Mice
  • Mice, Inbred BALB C
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / enzymology
  • Nitriles / pharmacology
  • Nitriles / therapeutic use
  • Tamoxifen / pharmacology
  • Tamoxifen / therapeutic use
  • Treatment Outcome
  • Triazoles / pharmacology
  • Triazoles / therapeutic use


  • Androstadienes
  • Aromatase Inhibitors
  • Enzyme Inhibitors
  • Estrogen Antagonists
  • Nitriles
  • Triazoles
  • Tamoxifen
  • Letrozole
  • exemestane